Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Oprozomib (Primary) ; Dexamethasone; Pomalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Amgen; Onyx Pharmaceuticals
- 17 Nov 2017 Planned End Date changed from 22 Dec 2017 to 30 Jan 2018.
- 17 Nov 2017 Planned primary completion date changed from 30 Sep 2017 to 30 Jan 2018.
- 20 Jun 2017 Planned End Date changed from 1 Oct 2017 to 22 Dec 2017.